Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of clonal diversity in cancer treatment resistance, through the outgrowth of resistant clones. In this Review, we focus on the genomic processes that drive tumoral heterogeneity and the mechanisms of resistance underlying metastatic breast cancer treatment and discuss implications for future treatment strategies.

中文翻译：

---

了解和克服转移性乳腺癌治疗中的肿瘤异质性

靶向治疗的合理发展已经彻底改变了转移性乳腺癌的结果，尽管对治疗的抵抗仍然是一个重大挑战。分子谱分析和成像技术的进步通过抗性克隆的生长，为克隆多样性对癌症治疗抗性的影响提供了证据。在这篇综述中，我们关注驱动肿瘤异质性的基因组过程和转移性乳腺癌治疗的耐药机制，并讨论对未来治疗策略的影响。